Literature DB >> 22976579

Completion of guideline-recommended initial evaluation of atrial fibrillation.

Moritz F Sinner1, Melissa A Greiner, Xiaojuan Mi, Adrian F Hernandez, Paul N Jensen, Jonathan P Piccini, Soko Setoguchi, Allan J Walkey, Susan R Heckbert, Emelia J Benjamin, Lesley H Curtis.   

Abstract

BACKGROUND: Guidelines recommend evaluation of cardiac function, valvular and ischemic heart disease, and thyroid, kidney, and liver function on initial diagnosis of atrial fibrillation (AF). HYPOTHESIS: We hypothesized that initial workup of patients with newly identified AF would vary by age, sex, and burden of comorbid illness.
METHODS: In a retrospective analysis of a large sample of commercially insured patients 18 to 64 years old (n = 40 245) and a nationally representative 5% cohort of Medicare beneficiaries 65 years or older (n = 204 676), we measured claims for guideline-recommended services for initial evaluation of AF among patients with a new diagnosis between 2000 and 2008.
RESULTS: From 30 days before through 90 days after AF diagnosis, basic evaluation, including physician visit, electrocardiogram, and echocardiography, was completed in up to 66.6% of patients. Completion rates for all guideline-recommended evaluations were 17.4% in the commercially insured sample and 18.5% in the Medicare cohort in 2007. Evaluation rates increased over time. Blood tests assessing thyroid function were documented for approximately one-third of patients in each cohort. Increasing the observation period to 1 year before through 3 months after the AF diagnosis markedly increased completion rates, but rates of thyroid function testing remained low (50%-60%). There were minor differences in evaluation completeness by sex, race, and geographic region.
CONCLUSIONS: Differences in guideline-recommended evaluation rates by demographic characteristics after a new diagnosis of AF were of minor clinical importance. Basic evaluation had satisfactory completion rates; however, rates of laboratory testing were low.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22976579      PMCID: PMC3652268          DOI: 10.1002/clc.22055

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  37 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis.

Authors:  M D Danese; N R Powe; C T Sawin; P W Ladenson
Journal:  JAMA       Date:  1996 Jul 24-31       Impact factor: 56.272

3.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

4.  Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation.

Authors:  Joseph A Ladapo; Guy David; Candace L Gunnarsson; Steven C Hao; Sarah A White; Jamie L March; Matthew R Reynolds
Journal:  J Cardiovasc Electrophysiol       Date:  2011-07-21

5.  Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.

Authors:  Donald M Lloyd-Jones; Thomas J Wang; Eric P Leip; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Ralph B D'Agostino; Joseph M Massaro; Alexa Beiser; Philip A Wolf; Emelia J Benjamin
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

6.  An alternative approach to age adjustment of cancer survival rates.

Authors:  Hermann Brenner; Volker Arndt; Olaf Gefeller; Timo Hakulinen
Journal:  Eur J Cancer       Date:  2004-10       Impact factor: 9.162

7.  Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.

Authors:  C T Sawin; A Geller; P A Wolf; A J Belanger; E Baker; P Bacharach; P W Wilson; E J Benjamin; R B D'Agostino
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

8.  Measuring and improving physician compliance with clinical practice guidelines. A controlled interventional trial.

Authors:  A G Ellrodt; L Conner; M Riedinger; S Weingarten
Journal:  Ann Intern Med       Date:  1995-02-15       Impact factor: 25.391

9.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.

Authors:  A D Krahn; J Manfreda; R B Tate; F A Mathewson; T E Cuddy
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

10.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

Authors:  E J Benjamin; D Levy; S M Vaziri; R B D'Agostino; A J Belanger; P A Wolf
Journal:  JAMA       Date:  1994-03-16       Impact factor: 56.272

View more
  4 in total

Review 1.  Women and atrial fibrillation.

Authors:  Annabelle Santos Volgman; Emelia J Benjamin; Anne B Curtis; Margaret C Fang; Kathryn J Lindley; Gerald V Naccarelli; Carl J Pepine; Odayme Quesada; Marmar Vaseghi; Albert L Waldo; Nanette K Wenger; Andrea M Russo
Journal:  J Cardiovasc Electrophysiol       Date:  2020-12-29       Impact factor: 2.942

2.  Thymosin β4 coated nanofiber scaffolds for the repair of damaged cardiac tissue.

Authors:  Arun Kumar; Arjun Patel; Louise Duvalsaint; Mehir Desai; Edward D Marks
Journal:  J Nanobiotechnology       Date:  2014-03-24       Impact factor: 10.435

3.  Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.

Authors:  Brent A Williams; Michael A Evans; Ashley M Honushefsky; Peter B Berger
Journal:  J Am Heart Assoc       Date:  2017-10-12       Impact factor: 5.501

4.  Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018.

Authors:  Brent A Williams; Alanna M Chamberlain; James C Blankenship; Elaine M Hylek; Stephen Voyce
Journal:  JAMA Netw Open       Date:  2020-08-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.